1stOncology™: Cancer Intelligence Service – Page 547 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

On June 1, 2026 UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, reported that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference to take place on June 8-10, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Goldman Sachs 47th Annual Global Healthcare Conference

Date / Time: June 10, 2026, at 8:40 AM ET
Format: Fireside chat and 1×1 investor meetings
Location: Miami Beach, FL
Webcast Link: here

The webcast from the conference will also be available on UroGen’s corporate website, under Events & Presentations. A replay will be available for approximately 90 days.

(Press release, UroGen Pharma, JUN 1, 2026, View Source [SID1234666319])

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

On June 1, 2026 Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, reported that it will host an R&D Day on Tuesday, July 14, 2026, at 8:30 AM ET in New York City. The R&D Day will feature presentations by Syndax’s management team and key opinion leaders.

The Company will highlight its late-stage revumenib and axatilimab programs, including its ongoing trials in idiopathic pulmonary fibrosis, newly diagnosed chronic graft-versus-host disease, and newly diagnosed acute leukemia. Further, the Company will detail its new early-stage assets and broader plans to leverage its capabilities and resources to bring new treatment options to more patients.

A live webcast of the event will be available on the Investor section of the Company’s website at www.syndax.com, where a replay of the event will also be available for a limited time.

(Press release, Syndax, JUN 1, 2026, View Source [SID1234666318])

The European Commission approves PharmaMar’s Zepzelca® (lurbinectedin) for the treatment of extensive-stage small cell lung cancer in combination with atezolizumab

On June 1, 2026 PharmaMar (MSE: PHM), reported that the European Commission (EC) has approved the combination of Zepzelca (lurbinectedin) with atezolizumab (Tecentriq) as a first-line maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC), whose disease has not progressed following standard induction therapy. This approval follows the positive opinion issued on March 27th by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) concerning this treatment.

Luis Mora, Managing Director of PharmaMar, points out that "it is great news that European patients and doctors now have access to a new treatment for this type of cancer. We believe it has the potential to change the paradigm of treatment for this disease, so we are looking forward to it being available soon in hospitals across Europe."

The approval is based on data from the Phase 3 IMforte trial, sponsored by Roche in collaboration with Jazz Pharmaceuticals, in which the combination of lurbinectedin and atezolizumab as maintenance treatment in first-line ES-SCLC was associated with a 46% reduction in the risk of disease progression or death and a 27% reduction in the risk of death compared with atezolizumab monotherapy.

In addition, lurbinectedin has been approved as an orphan drug, a designation granted by the EMA to medicines intended for the treatment of rare or uncommon diseases affecting fewer than 5 people per 10,000 inhabitants in the European Union.

Each year, around 62,000 new cases of SCLC are diagnosed in Europe, with most patients presenting advanced disease at the time of diagnosis .

Lurbinectedin in combination with atezolizumab has already been approved in 13 other countries, including the United States, for first-line maintenance treatment of this disease.

(Press release, PharmaMar, JUN 1, 2026, View Source [SID1234666317])

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

On June 1, 2026 Oncolytics Biotech Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, reported initial data from a preclinical study evaluating pelareorep in combination with RAS inhibitor modalities in a solid tumor model, which demonstrate evidence of greater anti-tumor activity in combination than with the individual approaches alone. Pelareorep is an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes.

Based on these findings, the Company is planning additional studies in models of pancreatic ductal adenocarcinoma ("PDAC") and colorectal cancer ("CRC") designed to further evaluate the combinations’ effects on immune activation, tumor response durability, and time-to-resistance. The ongoing work includes evaluations of pelareorep in combination with KRAS G12C inhibitors, pan-RAS inhibitors, and additional next-generation RAS pathway-targeting agents in RAS-mutated tumor models.

"We believe these initial findings further support pelareorep’s potential to serve as an immune-priming backbone for next-generation targeted therapies," said Jared Kelly, Chief Executive Officer of Oncolytics. "RAS-mutated tumors, particularly pancreatic and colorectal cancers, remain among the most difficult cancers to treat due to intrinsic immune resistance and the emergence of therapeutic resistance over time. These preclinical results support further study of the combinations’ anti-tumor and immune effects, including in models designed to assess durability and time-to-resistance."

Mr. Kelly continued, "Importantly, we believe this strategy may ultimately represent a potentially important area for further investigation in pancreatic cancer, where nearly all tumors harbor RAS pathway alterations and where patients continue to face extremely limited treatment options. The potential synergy observed in previous PDAC clinical studies and preclinical RAS-targeted modalities reinforces our belief that pelareorep may play an important role in future combination strategies designed to improve the durability of targeted therapies."

Full results from the initial preclinical studies are expected to be presented in the fall or winter of 2026.

(Press release, Oncolytics Biotech, JUN 1, 2026, View Source [SID1234666316])

NuCana Appoints Ian Webster as Chief Financial Officer

On June 1, 2026 NuCana plc (NASDAQ: NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, reported the appointment of Ian Webster as Chief Financial Officer, effective today. Ian has served as Interim Chief Financial Officer since June 2025 and was previously Director of Finance since joining NuCana in 2019.

"We are delighted to appoint Ian as Chief Financial Officer," said Hugh S. Griffith, Founder and Chief Executive Officer of NuCana. "Since joining NuCana, Ian has demonstrated deep financial expertise and a thorough understanding of our business. He will continue to shape our financial strategy as we advance our pipeline, including our plans to generate data in 2026 from the Phase 2 NuTide:701 study evaluating NUC-7738 in combination with Keytruda (pembrolizumab) in patients with PD-1 inhibitor-resistant metastatic melanoma and to prepare the optimal pathway toward a potential registrational strategy for NUC-7738 in melanoma."

"I am honored to be appointed Chief Financial Officer at such an exciting time for NuCana," said Ian Webster. "With multiple anticipated data readouts and a cash runway anticipated to extend into 2029, I look forward to helping advance the Company’s strategic priorities and long-term value creation."

Ian brings more than 20 years of finance experience to the Chief Financial Officer role, including over a decade in senior leadership positions within the biopharmaceutical sector. His expertise spans financial management, public company reporting, audit, tax, mergers and acquisitions, as well as financial planning and analysis.

Prior to joining NuCana, Ian served as Group Financial Controller at Kyowa Kirin International plc, a specialty pharmaceutical company, from 2013 to 2019. Earlier in his career, he spent 11 years at PricewaterhouseCoopers LLP, where he was a senior manager in the audit and transaction services practices in the United Kingdom and Canada.

Ian is a chartered accountant with the Institute of Chartered Accountants of Scotland and holds a BSc Honours in Accounting and Finance from the University of Warwick.

(Press release, Nucana, JUN 1, 2026, View Source [SID1234666315])